Cencora, Inc. (COR) SEC Filings & Earnings Calls

Regulatory clearance and AON stockholder approvals required; customary closing conditions.

“The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory clearances and AON stockholder approvals.” · word for word

Loss of board member with medical expertise; minimal operational impact as resignation is not due to disagreement.

“resignation is not due to any disagreement with the Company on any matter” · word for word

Customer concentration risk: Walgreens volume moving outside the company, though prime vendor agreement remains.

“certain Walgreens volume that was being serviced by Cencora separate from the prime vendor agreement began moving outside the Company”

Increased leverage capacity may signal future acquisition financing needs

“increase the aggregate amount of the commitments thereunder from $5.5 billion to $7.0 billion” · word for word

Opioid litigation liability

“Our accrued litigation liability related to the Distributor Settlement Agreement, as well as other opioid-related litigation for which we have reached settlement agreements on our Consolidated Balance Sheet as of June 30, 2026 is $4.2 billion and is expected to be paid over the next 13 years.” · word for word

Customer concentration

“We may lose a key customer if an existing contract with such customer expires without being extended, renewed, or replaced.” · word for word

GLP-1 margin pressure

“offset in part by higher sales of GLP-1s, which have lower gross profit margins.” · word for word

Integration risk from OneOncology acquisition and increased leverage from debt financing

“Interest expense increased $58.9M due to senior notes and term loans for OneOncology acquisition”

GLP-1 sales mix pressure on gross margins due to lower margin profile

“offset in part by increased sales of GLP-1s, which have lower gross profit margins” · word for word

CFO transition risk

“Retirement of James F. Cleary and appointment of new CFO Eva C. Boratto, with advisory period through end of 2026.”

Customer concentration and loss

“a decrease in sales due to losses of an oncology customer and a grocery customer, and lower sales to our large mail order customer as a result of brand conversions” · word for word

Opioid litigation liability

“Our accrued litigation liability related to the Distributor Settlement Agreement...as of March 31, 2026 is $4.3 billion and is expected to be paid over the next 13 years.” · word for word

Interest expense increase from acquisition debt

“Interest expense, net increased by $36.5 million, or 35.1%, from the prior year quarter due to the increase in interest expense and a decrease in interest income.” · word for word

GLP-1 drug sales impact on gross margin; lower margin product mix.

“Higher sales of GLP-1s, which have lower gross profit margins.” · word for word

Regulatory approval risk.

“Transaction subject to regulatory approvals.”

CFO transition may cause temporary uncertainty.

“Retirement of CFO effective June 30, 2026, with no successor named.”

Regulatory approval risk; transaction may not close as expected.

“Subject to customary closing conditions, including regulatory approvals.”

Increased leverage from $3.0B debt issuance, though used to refinance existing debt.

“Issued $3.0B in senior notes; proceeds used to repay existing credit facility.”

Increased leverage from $3.0B debt issuance, though used to refinance existing debt.

“Priced $3.0B in senior notes; proceeds to repay existing credit facility.”

Customer concentration and contract renewal risk

“A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a key customer if an existing contract with such customer expires without being extended, renewed, or replaced.” · word for word

Opioid litigation liability

“Our accrued litigation liability related to the Distributor Settlement Agreement and an estimate for non-participating government subsidiaries... as of December 31, 2025 is $4.3 billion and is expected to be paid over the next 13 years.” · word for word

Impairment of assets

“We recorded an impairment of assets of $249.5 million, including goodwill, related to our U.S. Consulting Services business that was classified as held for sale as of December 31, 2025.” · word for word

Impairment of assets in U.S. Consulting Services business held for sale

“$249.5 million impairment of assets related to its U.S. Consulting Services business that is classified as held for sale.” · word for word

Interest expense increase due to debt financing for acquisitions

“Net interest expense was $72.4 million, an increase of $44.5 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and a variable-rate term loan to finance a portion of the January 2025 acquisition of RCA.” · word for word

Customer Concentration Risk

“In fiscal 2025, transactions between the Company and WBA accounted for approximately 25% of our revenues and 38% of our accounts receivable, net, as of September 30, 2025.” · word for word

Opioid Litigation Risk

“The distribution of opioid medicines represents less than one percent of our annual revenue, and we do not offer our sales team members incentives based on opioid sales.” · word for word

International Segment Underperformance

“The Compensation Committee exercised discretion and reduced the total payout percentage to 181.3%... in recognition of the underperformance of a business within our International Healthcare Solutions reportable segment.” · word for word

Increased leverage from new credit agreements may raise financial risk, but no specific amounts or terms provided.

“Creation of Direct Financial Obligation under Item 2.03; multiple credit agreements executed.”

Integration risk and regulatory approval uncertainty for large acquisition.

“subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals” · word for word

Increased leverage from debt financing may pressure credit rating.

“fund the transaction through new debt financing, and has obtained $4.5 billion in bridge financing commitments” · word for word

Opioid Litigation Liability

“Our accrued litigation liability related to the Distributor Settlement Agreement ... was $4.3 billion as of September 30, 2025.” · word for word

Customer Concentration

“our two largest trade receivable balances due from customers (Walgreens and Boots together and Evernorth Health Services) represented approximately 38% and 5% of our accounts receivable, net.” · word for word

IRA Drug Pricing Impact

“The Inflation Reduction Act ('IRA') made significant reforms affecting prescription drug pricing and reimbursement.” · word for word

Goodwill Impairment Risk

“it recorded a full impairment of the remaining goodwill of $723.9 million in the PharmaLex reporting unit.” · word for word

Goodwill impairment charge of $723.9 million related to PharmaLex indicates potential integration challenges.

“$723.9 million goodwill impairment charge related to PharmaLex in the current year period.” · word for word